Navigation Links
Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis
Date:11/23/2009

blank' href="http://www.raptorpharma.com/patients_nash.html">non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase ("ALDH2") deficiency, and a non-opioid solution designed to potentially treat chronic pain.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: that Raptor will start a Phase 3 clinical trial in cystinosis patients at multiple US and European sites in the first quarter of 2010, if at all; that DR Cysteamine may allow for a 30% reduction in a patient's total daily cysteamine dose compared to the current standard of care; that DR Cysteamine can be administered in two doses per day instead of four, to achieve the same pharmacodynamic result; that tolerability of DR Cysteamine, as demonstrated in this study, potentially represents a major step forward in the care of cystinosis patients; that Raptor's formulation could result in greatly improved dosing compliance and better long-t
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
2. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
3. Raptor Pharmaceutical Expands Board of Directors
4. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
5. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
6. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
7. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
8. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
9. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... WORTH, Texas , December 18, 2014 /PRNewswire/ ... a networked software application/module that is used to ... related images. RIS comprises a patient tracking and ... system. The integration of RIS with HIS and ... used for patient registration and patient scheduling, patient ...
(Date:12/19/2014)... REDWOOD CITY, Calif., Dec. 18, 2014 ... on the development of medical diagnostics based on ... of gas flow, today announced financial results for ... 30, 2014. "Following the completion of ... well positioned to maximize the recently initiated CoSense® ...
(Date:12/19/2014)... , Dec. 19, 2014  Eli Lilly and ... Paris: FR0011184241 – ADOC) today announced a worldwide licensing ... BioChaperone Lispro, for treatment in people with type 1 ... proprietary BioChaperone® technology and is currently in Phase Ib ... Lispro with the goal of optimizing glucose levels during ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... , MORRISTOWN, N.J. , May 24 Watson ... subsidiary, Watson Laboratories, Inc., has received approval from the United States ... for Valacyclovir Hydrochloride tablets, USP, in the 500 and 1000 mg ... to begin shipping the product shortly.   , ...
... Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at ... government $175 million in unlawful profits from the sale of products that ... , , ... , , ...
Cached Medicine Technology:Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 2Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 3Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3
(Date:12/21/2014)... 21, 2014 Khanna Vision Institute is ... at the Aspen Helicopters holiday event for underprivileged kids. ... with sleigh, flown by an aspen helicopter pilot. In ... Santa with sleigh was visible.(please see accompanying video). Helicopter ... Dr.Khanna has helped many pilots with Pi in eye ...
(Date:12/21/2014)... HealthDay Reporter FRIDAY, Dec. 19, 2014 ... than traditional cigarettes, new research finds. Even though ... thousands of ex-smokers said they have fewer cravings and are ... to smoke, researchers reported. "The pattern was ... use than for tobacco use," said lead researcher Jonathan Foulds, ...
(Date:12/21/2014)... Serious Buyer, Andrew Hawley from Vintage Rock ... the Doors International Ballroom at the Hilton Hotel in ... only time that Morrison's mother would see her son ... According to Hawley, “This would be the Doors only ... Roller Rink earlier that year and would return to ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Theme ... announced a new intro plugin for Final Cut Pro ... pictures, videos, logos, and more with absolute ease.” Said ... our users the tools needed to easily animate their ... Final Cut Pro X users to animate pictures, videos, ...
(Date:12/21/2014)... Concept Plus, LLC. a SDB and ... Fairfax, VA., today announced it has been recognized by ... which ranks the fastest growing government contracting small businesses by ... , This is the first year that Concept Plus, LLC., ... with a 95.92% compound annual growth rate. “For Concept Plus ...
Breaking Medicine News(10 mins):Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2
... has a new man in her life, this time, a 21-year-old ... pills like Vicodin and Rohypnols so that he would be ... Atkins, whose label Rock Stars and Angels, is available in trendy ... on July 15. ,And sources have revealed that the ...
... to a study published in the Neurology, the medical journal ... are more likely than women without cognitive decline to ... the study, 2,474 women with an average age of 69 ... 15 years. Sleep problems were measured at the end of ...
... back, the Food and Drug Administration approved a new birth ... pregnancy as the other pills already in the market , ... will never get their periods. ,Lybrel is landing ... the same- it may disappear altogether. ,Already the ...
... pound man stuck after a tubing accident was rescued from St. ... attack when in the river and he was rescued by dozens ... navigable part of the waterway. ,Martin Rike, 39, of ... down the river. They were floating down the river on the ...
... of published literature about benefits and harms of ... that older agents , such as second-generation sulfonylureas ... glycemic control, lipids and other intermediate endpoints compared ... alpha-glucosidase inhibitors and meglitinides. ,This is ...
... today called for a nationally co-ordinated capital funding source ... students in the general practice setting. ,Articles ... highlighted the need for the expansion of medical education ... ,With the rapid increase in medical student numbers, we ...
Cached Medicine News:Health News:Memory Problem in Older Women Lead to Restless Nights 2Health News:The Queen Of All Contraceptives Released 2Health News:500 Pound Man Rescued After 12 Hour Ordeal From Wisconsin River 2Health News:Medical Education in General Practice: A Way Forward 2
BD Vacutainer® Specialty Tubes - Trace Element - Plastic...
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: